New Evidence and Novel Therapies for Severe Asthma Management - European Medical Journal

New Evidence and Novel Therapies for Severe Asthma Management

Download PDF
*Caroline Charles

Medical writing assistance was funded by Novartis.

EMJ Respir. ;2:50-57. DOI/10.33590/emjrespir/10311507.
fevipiprant, ligelizumab, mepolizumab, omalizumab, QAV680, QAW039, QGE031, QMF149, reslizumab

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


The 2014 European Respiratory Society International Congress, held last month from 6th-10th September in Munich, Germany, provided a platform for key opinion leaders in the field of asthma management to disseminate new clinical data and recent developments. Despite the use of high-dose inhaled corticosteroids and long-acting β2 agonists, a proportion of patients still have uncontrolled disease and are at risk of exacerbation and hospitalisations, thus requiring the use of intermittent or continuous oral corticosteroid therapy. In severe uncontrolled asthma, exacerbations can be potentially life-threatening, and are the main cause for morbidity and mortality in asthma patients, necessitating considerable healthcare resource utilisation. Consequently, there remains an unmet need for newer therapies to manage asthma in several patient subsets, for which current therapeutic options do not yield adequate benefits and outcomes.

Please view the full content in the pdf above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally